BridgeBio (BBIO.US) heart disease therapy acoramidis outperforms Pfizer (PFE.US) competitor drug in real-world study

Zhito Finance APP has learned that BridgeBio Pharma (BBIO.US) announced on Wednesday that its heart disease therapy acoramidis (brand name Attruby in the United States) outperformed Pfizer's (PFE.US) competing drug tafamidis (brand name Vyndamax in the United States) in a real-world study.